AS01B adjuvant mechanisms and CD4 T cell responses

AS01B induces robust and durable CD4 T cell responses via a two-phase mechanism

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria.

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine.

Screening

We screened in sources based on their abstracts that met these criteria:

• AS01B Adjuvant Focus: Investigates AS01B adjuvant specifically.
• CD4 T Cell Response Measurement: Measures CD4 T cell responses as primary or secondary outcomes.
• Appropriate Study Type: Human clinical trial or animal study using established laboratory models.
• AS01B Data Availability: Includes AS01B data.
• CD4 T Cell Data Inclusion: Includes CD4 T cell data.
• CD4 T Cell Response Focus: Includes CD4 T cell response data.
• AS01B Effect Attribution: Attributes effects specifically to AS01B.
• Full Publication Status: Full-text publication.

Data extraction

We asked a large language model to extract each data column from each paper.

• Study Context: Key study design information relevant to AS01B mechanisms and CD4 T cell responses.
• AS01B Mechanisms: Mechanistic data showing how AS01B works at the innate immunity level.
• CD4 Responses: CD4 T cell response data specifically for AS01B.
• Mechanism-Response Links: Evidence directly connecting AS01B mechanisms to CD4 T cell responses.
• Adjuvant Comparisons: Comparative data between AS01B and other adjuvants.
• Key Findings: Main conclusions about AS01B adjuvant mechanisms and CD4 T cell responses.

Results

Characteristics of included studies

The included studies span multiple vaccine platforms and species, with three studies using full-text data and seven relying on abstract-only information. Studies evaluated AS01B across diverse antigens including malaria, herpes zoster, hepatitis B, and HIV-1. Study populations included healthy human adults, mice, and rhesus monkeys.

AS01B mechanisms at the innate immunity level

AS01B consistently induced IFN-γ production across multiple studies, demonstrating that AS01B induced transient innate responses including IL-6 and CRP, with increased IFN-γ levels after the second injection.

CD4 T cell responses induced by AS01B

AS01B consistently induced robust CD4 T cell responses across diverse antigens and species.

Comparative adjuvant effects

AS01B demonstrated superior CD4 T cell induction compared to all tested adjuvants.

Mechanistic links between AS01B activation and CD4 T cell responses

The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses, which underscores the significance of the differential pathway activation in enhancing vaccine immunogenicity.